[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] An update on the current state of SARS-CoV-2 Mac1 inhibitors
JJ O'Connor, D Ferraris, AR Fehr - Pathogens, 2023 - mdpi.com
Non-structural protein 3 (nsp3) from all coronaviruses (CoVs) contains a conserved
macrodomain, known as Mac1, that has been proposed as a potential therapeutic target for …
macrodomain, known as Mac1, that has been proposed as a potential therapeutic target for …
Chemoenzymatic and synthetic approaches to investigate aspartate-and glutamate-ADP-ribosylation
K Tashiro, S Wijngaarden, J Mohapatra… - Journal of the …, 2023 - ACS Publications
We report here chemoenzymatic and fully synthetic methodologies to modify aspartate and
glutamate side chains with ADP-ribose at specific sites on peptides. Structural analysis of …
glutamate side chains with ADP-ribose at specific sites on peptides. Structural analysis of …
The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature
GJ Correy, DW Kneller, G Phillips, S Pant, S Russi… - Science …, 2022 - science.org
The nonstructural protein 3 (NSP3) macrodomain of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2)(Mac1) removes adenosine diphosphate (ADP) ribosylation …
coronavirus 2 (SARS-CoV-2)(Mac1) removes adenosine diphosphate (ADP) ribosylation …
[HTML][HTML] A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo
Despite unprecedented efforts, our therapeutic arsenal against SARS-CoV-2 remains
limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP …
limited. The conserved macrodomain 1 (Mac1) in NSP3 is an enzyme exhibiting ADP …
[HTML][HTML] PARP14 is a writer, reader, and eraser of mono-ADP-ribosylation
A Torretta, C Chatzicharalampous… - Journal of Biological …, 2023 - ASBMB
PARP14/BAL2 is a large multidomain enzyme involved in signaling pathways with
relevance to cancer, inflammation, and infection. Inhibition of its mono-ADP-ribosylating …
relevance to cancer, inflammation, and infection. Inhibition of its mono-ADP-ribosylating …
Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening
The emergence of several zoonotic viruses in the last twenty years, especially the pandemic
outbreak of SARS-CoV-2, has exposed a dearth of antiviral drug therapies for viruses with …
outbreak of SARS-CoV-2, has exposed a dearth of antiviral drug therapies for viruses with …
[HTML][HTML] The conserved macrodomain is a potential therapeutic target for coronaviruses and alphaviruses
Background: Open Access Perspective The Conserved Macrodomain Is a Potential
Therapeutic Target for Coronaviruses and Alphaviruses by Anthony KL Leung 1, 2, 3, 4 …
Therapeutic Target for Coronaviruses and Alphaviruses by Anthony KL Leung 1, 2, 3, 4 …
DTSEA: a network-based drug target set enrichment analysis method for drug repurposing against COVID-19
Y Su, J Wu, X Li, J Li, X Zhao, B Pan, J Huang… - Computers in Biology …, 2023 - Elsevier
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic is still wreaking havoc
worldwide. Therefore, the urgent need for efficient treatments pushes researchers and …
worldwide. Therefore, the urgent need for efficient treatments pushes researchers and …
[HTML][HTML] MolData, a molecular benchmark for disease and target based machine learning
Deep learning's automatic feature extraction has been a revolutionary addition to
computational drug discovery, infusing both the capabilities of learning abstract features and …
computational drug discovery, infusing both the capabilities of learning abstract features and …